FKBP1A
Peptidyl-prolyl cis-trans isomerase FKBP1A
As of the edition of 20 October 2026, FKBP1A (peptidyl-prolyl cis-trans isomerase FKBP1A, UniProt P62942) has 8 drugs tested at it and 13 companies on the list, 1 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P62942
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 114
- Disease areas
- Cancer; Immune system; Blood and lymph; Urinary and reproductive; Skin and connective tissue; Pregnancy and women's health; Inherited and neonatal; Heart and blood vessels
- Registered trials of its drugs
- 2,254
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tacrolimus anhydrous | Marketed | Phase 4 | Ends 2028 |
| Everolimus | Marketed | Phase 4 | none listed |
| Sirolimus | Marketed | Phase 4 | none listed |
| Temsirolimus | Marketed | Phase 3 | none listed |
| Pimecrolimus | Marketed | Phase 4 | none listed |
| PTX-022 | Active | Phase 3 | none listed |
| SEL-110 | Stopped | Phase 1 | none listed |
| FK506E | Went quiet | Phase 3 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 6 |
| Engaged | 6 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Astellas | Route B |
| Nobelpharma | Route B |
The other 10 companies at FKBP1A
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at FKBP1A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.